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Executive
A

Summary

content analysis of pharmaceutical product ads

professional media was conducted
as well as the
selected was

on

been documented to

results

indicate that
=

(6. 1).

notable was

95%

OTC

71% identified the disease

typically found

not

to

whereas

product,
used

52%

The study

content analysis model
standards that

analyzed

67

It

influence

on

targeted

appears

higher

number of information

ads

Most

drug ads were perceived to be overly weighted with

defiance

of FDA regulations.

illustrated

or condition

In addition,

while over

product

benefits

and

for which the

product

is indicated. Ads were

information

of ads contained

any

on

characteristics, only

dosing or treatment directives.

scientific

contained emotional cues.

information in

These data

that the advertising agencies may be

advertising copy than is

audience.

separate

during the first half of

support of the

suggest that

by pharmaceutical companies to communicate with physicians is not

rational.

have

help in educating and Morming the physician.

products contained a

contain much

Surprisingly, only 35%

The

they were informative

patterns of information content within the ads emerged.

apparent

of prescription and

which

pediatrician-targeted journals

of prescription

benefit information, in

to

each pharmaceutical product ad contains an abundance of

launched

Distinct

that 53%

in

5.1 cues) that may

support of newly

cues per ad

extent

widely implemented

support research propositions.

information (average

Ads in

published and

previously

products ads that were published

2002. The

to determine the

and types of information presented.

quantity

based

targeted toward pediatricians in the

expected

the approach

sufficiently

having a more profound

considering the

professional status of the

Introduction
Physicians
Consumer

(DTC)

are exposed

challenged with
while

vehicles,

the bulk of this

stringent

in the form

To

of Direct

medical education and

pharmaceutical product manager

in

is

across the entire gamut of promotional

budgetary goals. Whereas,

investment in

increased from $9.2 billion in 1996 to $15.7 billion in 2000,

increased investment has

to the physician

has declined (2). Thus,

occurred

in DTC,

and the expense of promotion

the advent of DTC has profoundly impacted the

by pharmaceutical companies to advertise products to their customers.

There is

much

debate

(3). Although proponents

over

ultimately

receive

the motives

behind

of DTC argue that such

directly in their own healthcare,
patients

today's

effectively allocating funds

pharmaceutical promotion

modes used

Therefore,

maintaining

promotion

force detailing, continuing

sales

advertising,

the professional media (1).

to pharmaceutical

has

today's constrained managed

pharmaceutical

advertising

DTC advertising

programs

involve

patients

the potential impact on the standard of healthcare that

yet to

care

be

fully determined.

environment,

Studies have

physicians might

be

shown

that in

prompted to

comply

by prescribing what consumers demand rather than take the time and effort (and cost) to
complete a

profits,

full diagnosis (3, 4). There is

the danger that in a blinkered quest for

pharmaceutical companies might even exclude

One

communication process.

which

also

example

involves the

the

physician altogether

anti-cholesterol

in the

drug, PravachoL

targeted only consumers (5). The result was that physicians preferentially

prescribed the

is

managers

one of a

the healthcare
partner

competing brand Lipitor (5). Thus, the prevailing

balanced

promotional program

"gatekeeper"

and

incorporates

message to product

that acknowledges the physician as

physician-targeted communication as a vital

to DTC.

With
quantified

respect

to the logic behind a balanced promotional campaign, it has been

that dollars have been diverted away from professional journals over the past

ten years in favor of increased sales

advertising (6). In 2000
advertising declined

(6). This

by

escalation of

dictates that

-

forces,

educational programs and most

2001, spending by pharmaceutical

13%

notably DTC

companies on journal

(7) while expenditures on sales forces has grown by

16%

inter-company competition for valuable time with the physician

sales representatives

invariably end up at the receptionist's window or

receive

only

minutes of face time with the

information flow to the physician
important information

Thus,
in the

on

in the

communication process

return on

addition

a

compels

between

than either sales

the

physician

the

to acquire

pharmaceutical
showed

imperative

may play

a more

company

and physician

journal advertising to

force detailing, DTC,

role

than ever

provide a greater

or medical education

(9). In

being cost-effective, journal advertising is also described as a preferred source

of information

for physicians,

assimilated at times
suggest that

presented

determined by the

if physicians

in

a

user-friendly format

physician

receive all of their

15).

(6,

information

But,
about

and with

highlight the

need to

better

pharmaceutical companies

This study

comprehend

drugs from advertising

fill the

pharmaceutical advertisements
guide product managers as

void

viewpoints

the informational content currently provided

to physicians through the

seeks to

information

alternative viewpoints

then health care may be compromised (1). These apparently contrasting

order

compromises

sources.

professional media

2001 independent study

investment

to

moreover,

drugs from alternate

advertisements

before. Indeed,

and

doctor (8). Such limited time

professional media.

in the literature regarding the

content of

to physicians. As such, the study is designed to

they develop

by

advertisements

for the

help

professional media.

In

to perform a manageable research study, only those ads targeted toward a subgroup

of physicians,

pediatricians,

Pediatric Journals

in which to

are

were used as a paradigm

easily identifiable by title

and

for

medical

advertising

thus represent

as a whole.

an accessible vehicle

identify patterns of pharmaceutical advertising to physicians.

Research Objectives
The

study is to investigate the

objective of this

healthcare products to

and

pediatricians as a paradigm

practices to physicians overall.

While there is

a

for

Propositions
to

approaches used

advertise

pharmaceutical promotional

paucity

of published content analyses of

pharmaceutical product advertisements targeted toward the medical professional, there
an abundance of research

Typically,

research models were

information
choices

dedicated toward

cues

based

from among

upon

alternatives

comparing the information
articles

(11,

investigated

14

12). Analysis

consumer

developed from a

advertising using the

classification system

criteria contained within an ad that

(13). Studies

were

between U.S.

content

printed media.

for advertising

facilitated intelligent

geared, for example, toward

Japanese

and

of pharmaceutical product ads

specific characteristics

is

or

Indian

magazine

directed toward

relating to both disease

consumers

state and product

has

including

(10):
Market

size

Drug usage
Side

effects

Lifecycle

While these

basic

stage

criteria were

developed specifically for

tenets of the models serve as the

influencing factors such as drug usage,
in

association with specific

between

ads.

In addition, the

The

cues

presentation of the ad will

determine the

are

be

advertising, the

Thus,

lifecycle

to discern patterns

the

will

impact

be

of

analyzed

of content within and

characterized

from

a rational

mode of communication of the message

to the

influencing factors deemed most relevant to pharmaceutical product ads

formed the basis for the hypothesis development
factor

analysis.

side effects and product

informational

and emotional standpoint to
audience.

foundation for this

consumer

discussed in

more

used

in this

study.

Consequently,

these

detail below.

Prescription Drugs
Pharmaceutical

categories, those that

product advertisements

are available

in the

professional media

only by prescription

and

fall into 2

those that are available

over-

(OTC). In

the-counter

the products use

(21 CFR

202.1)

or

prescription advertisements wherein claims are made

Drug Administration statutory requirements

effectiveness, the Food &

Brief Summary

mandates of a

detailed information

about the

This Brief Summary

must also contain clinical

adverse reactions that

may

of Product

drug, its dosage,

data

there is an

Consequently,

drugs that

prescription
prices.

less

In contrast, OTC

Because

advertised.

informational

content

HI: Ads to

between

drugs,

advertisement contains a

presented

information

in

will

will

there

comparable

test

do

is

an

any

is

advertising.

be

support

commodities and

OTC

higher

consequently

for differential

patterns of

products.
prescription

communicating

drug's benefits

of the product should

on the

safety

depth

(Rule for judgment:

with physicians.

risks. The

be approximately balanced

both drug benefit

detail. Thus, there is

fair balance in

ethical obligations

and

body of an

and risks associated with the product.

states that

and

contain such

expected

FDA requirement that the

of a

whether ads are perceived

investigate the

conformity is

to

likely to be

Balance"

21 CFR 202. 1(e)(5)

advertisements

study

investment in

potential exists

prescription and

"Fair

indicate that copy in favor

requirement

the Brief Summary

protected and thus can command

differences,

physicians are more

prescription

appropriate

Typically,

and report

following page.

an

products are speculated

of these

drug's efficacy

Risks

and

For

for

the

that the majority of product ads

typically patent

provides

HI if >50%)

accept

Benefits

expectation

are

on

occur after administration.

a substantial return required

Characteristics that

administration and contraindications.

provided either adjacent to the actual ad or on the

There is

regarding

to be

and risk

by
The statutory

information be

an expectation

accordance with

requirements

that prescription

FDA guidelines. This

fairly balanced by the reader,

and as such

that pharmaceutical companies adhere to in

A high level for the judgment

was set

because majority

due to FDA regulations.

H2: Prescription Ads
(Rule for judgment:

contain

accept

fairly balanced

H2 if >80%)

statements of

benefits

and risk

Stage

of

Product Lifecycle

One
media

for the

explanation

is the lack

recent

of new product

decline in advertising

introductions,

advertising investment (7). Also, it has

been

has declined due to the

maintenance products

Interestingly,

also

launches may be

new product

and the

expenditures

expense

from

budgets

advertisements
"new."

doing

"lesser"

proposed

that the advertising of

number of new

advertised with

introductions (6).

discrete informational

for new

products

H3:

Many advertised

judgment:

accept

to take

have larger

"introducing"

or

such as

proportion of ads that contain new products and

any distinct informational

correlate them with

order

The

comprehensively.

typically contain identifiers

quantify the

will

in

recognized that such new products

therefore can be advertised more

and

This study

drugs. It is

medical

corresponding decrease in the

content that positions the product with unique competitive advantages
market share

in the

products

in

so

cues.

tend to be early in their life cycle (Rule for

H3 if >30%)

Informational Cues

The

crux of the analysis

a viable source of information
employed

by Resnik and

characteristics,

Stern model,
information

scientific

ads were

cues

indicate that the
and

(13,

is

pediatricians.

targeted pharmaceutical ads are

from that

model was adapted

Stern

(13, 14) to include

data,

safety, and treatment (Appendix 1). In the Resnik

14). At

such a

proposed that

14 information

cues such as product

contained just

low stringency, it's

not

1

higher level

expected

in

informative only if it

of factual and

consumer ads.

regulatory guidelines.
contains at

and

of the selected

surprising that

some reports

between 75%

the nature of the pharmaceutical business obligates

role that pharmaceutical companies
of federal

The

deemed to be informative if they

companies to provide a

than

for

understand whether

proportion of informative consumer-targeted ads ranges

85% (1 1). It is

products

is to

This

play in health

Therefore,
least 4

beneficial information regarding their

proposal
care

is based

upon

the

important

delivery and due to the presence

this analysis proposes to classify an ad as

of the selected

information

cues.

H4: The majority of product advertisements can be deemed as informative
(Rule for judgment: accept H4 if >50% of ads contain >4 information
criteria)

Disease Identification
Identification

important
can

be

disease to be targeted

of the

aspect of the
"off-label"

used

informative process. On the
for the treatment

specifically indicated. Thus

pharmaceutical

resulting in

impact

HS: Ads to

hand,

than those

may purposely

is indicated thus

pharmaceutical

not

drugs

for which the

drug is

identify the particular

facilitating "off-label

use"

on corporate revenue.

pediatricians

judgment: accept

other

of diseases other

pharmaceutical ads

disease for which the
a positive

by a particular drug might be an

identify the disease to

be treated (Rule for

H5 if >50%)

Treatment Directives
An important
ad might

be to

provide

regarding the type

possibility that
provide

component of the

direction

of patient

ads will not

directions

in

on

information

the use

whom

the

of the

delivery process for a pharmaceutical

drug,

when

drug can and should be used.

on

on the use of the

the drugs

data would be
disease

states

usage

is

H6: Ads

provide

or

Even

with

drug. Moreover, there is potential for

provided

suggestive of ads

in which the

drug,

the

identify the disease to be treated, they nevertheless may

dichotomy in that the disease may not be identified (i.e.,
direction

to use the

(i.e.,

H6 is

rejection of

not rejected).

an

H5) but

interesting

specific

In this scenario, the

being exquisitely designed to maximize profits even for

drug has not been indicated or otherwise not proven effective.

direction

on

the

use of

the

drug (Rule for judgment:

accept

H6if>50%)

Scientific Data
The

goal of the pharmaceutical product manager

the qualities of a

drug and the impact it might have on the patient. Thus,

targeted toward physicians might be expected to

outlining the
competitor

effectiveness of the

treatments.

by emotion.

product ads

display a variety of scientific data

question contributes

decisions based

The

physician about

drug in order that comparisons can be made to

Moreover this

whether physicians make

motivated

is to inform the

original

to the

upon rational scientific

Resnik

and

8

Stern

model

determination

information or

focused

on

of

are

discerning

data from independent

company-sponsored

discrimination was
product

retained

efficacy data

in the

research

(13). While the

current model used

and scientific

data in any form was additionally

order

well recognized

validate product

that ads need to be oriented to the specific

to be effective, and this basic marketing

(15). For example, information

benefits

factors

can

influence

goal of the ad

demonstrations

read and take action.

unaided, and few

Thus,

to be

be

However,

physicians can

rather

than

based

viewpoint of Daniel

subsequent

in the

Starch; "...

to advertising

motivate

appeal

to

regarding the headline

(15, 16,

physicians

17).

leverage

pediatricians.

and

using

to

scientific

cues

have only

(Rule for judgment:

accept

a

consistent with the
weak

product characteristics and
was assessed

and more

limited

data)

(26). Thus, in this study the

Emotion

body copy,

of the

(27).

using

role

H8 if <20%)

a

indirectly by virtue of

analysis of the creative artwork associated with the ad.

H8: Emotion stimulating

to

ads are recalled

is the initial impact

(e.g.,

facts"

whether ads

series of questions

2)

the fact remains that superlative generalities are

designed to investigate
to

content

This hypothesis is

advertisement.

questions were

emotion

ad recall studies.

pharmaceutical companies appeal

a statement of

than

its

of the entire ad

reading

far less convincing than

rather

ad or

objectives

arguments and

benefits

using

Various

to get noticed, be easily assimilated, validate claims

upon a rational approach

on emotional cues

group in

for physicians

of economic value.

measured

accurately describe the

The theory to be investigated is that
pediatricians

encouraged

indicates that very few

Of central importance to these

headline that may influence the

be

attention of the physician and

market research

successful an ad needs

remembered.

be

ad performance and these can

is twofold; 1) draw the

customer

theory applies to healthcare professionals

on symptom relief would

while managed care officials might prefer

and

collected.

presentation: the role of emotion

It is

The

such

in this study, information regarding

H7: Scientific data is an important tool used to
(Rule for judgment: accept H7 if >50%)

Ad

for

potential

in

informing

Research Methods
Content

healthcare
for

products

content analysis

to

physicians

in the

professional print media.

includes objectivity,

(18). Moreover,

components

to investigate the approaches used to advertise

analysis was used

quantification and

content analysis

The basic methodology

reliability

has been described

as a useful method to

establish whether patterns support research propositions with regard

(18,

19). Although

consumer

such research

has typically been targeted toward

advertising, thus mandating some

as essential

to the print media
evaluation of

reasonable adaptation prior to use as a tool to

evaluate pharmaceutical advertising.

In this study,
physicians,
aim was

were

advertisements targeted toward
selected

specifically

pediatricians,

a

by utilizing six widely read pediatric journals.

to analyze all product advertisements in these journals from

2002. This technique
sample selection.

was

implemented in

The journals

discrete subgroup

order

The

January to June

to remove the bias associated

with

Pediatrics, Pediatric News, Infectious

used were:

Diseases of Children, Pediatric Research, The Pediatric Infectious Disease Journal,
Archives ofPediatrics and Adolescent Medicine.

journals that

range

Infectious Diseases

from

peer-reviewed journals

of Children

of

These

and

represent a cross section of

to magazines such as Pediatric News and

that provide brief news and commentary on clinical

developments. While this study is

not

designed to determine

where physicians get their

information, it does provide information on the content of ads across the breadth of
journal types
studies were

selected.

based

1)

and reliability:

As dictated

(18, 19),

three specific criteria were employed to ensure objectivity

establish clear rules and

ensure

judge independence

Rules

and

definitions, 2) provide judge training,

and

3)

and reliability.

Definitions

The

analysis was performed

categories or

were

by the models of content analysis on which these

information,

informed

on a sample

the majority

of the objectives of the

pharmaceutical ad

questionnaire

using

is

supplied as

a

1-page

questionnaire

of responses

study,

to

that contained various

which were

"yes

no."

Judges

or

and were asked to complete a questionnaire

by way of discussing each of the categories.

Appendix 2.

10

The

Judge Training
Judge training is important for both
exposed to the operational

approximately 1-hour
concepts, definitions

definitions

Judge Independence

and

and

categories, e.g.,

a

were used

director

comprehending the language

judges be

accuracy

for evaluating the

high degree

the

each

suggested as an

(note: 3

a

ads were

healthcare

family practice

To

resulting from the data analysis, it is imperative that

and were under no

time

constraint.

Judges were

In

order

selected to

to interpret

of accuracy, statistical measurements of the coefficient of

coefficient

accuracy

between judges).

guideline

deleted from the

as well as

for

(20).

(20).

a value

Ir

because

ranged

11

Ir

ranged

of irreconcilable

from 0.8 1 to 1

.00

disagreements

from 0.70 to 1.00 (Appendix 3). Where

were resolved

input.

OveraU,

that exceeds the Ir of 0.70

By advertisement,

analysis

By coding category,

Reliability coefficients were

each product advertisement.

(Ir) was 0.88,

necessary, discrepancies between judges
author's

marketing,

distinct

associated with pharmaceutical product advertisements.

coding category

inter-judge reliability

on

Thus, they were eminently capable of

agreement were calculated prior to reconciliation

for

on

enabling direction

content of 67

able to make autonomous assessments of the content.

results with a

of

emotion.

of pharmaceutical

of conclusions

be completely independent

calculated

well as

focused

possessed considerable experience across the

physician and a rehabilitation counselor.

ensure the

facilitated discussion

attention was

the ad as

Judges were

by way of an

questionnaire

Particular

reliability.

Reliability

The judges

included

inter-judge

use of a sample ad

statements within

Three independent judges

industry,

in the

and potential conflicts.

some of the more subjective

advertisements.

This

presentation.

fair balance

evaluation of the

used

intra- and

by discussion and with this

Results
The

results represent patterns

for

pediatricians

on printed ads

journal advertising in the

in the

that were in support

informational

(Appendix 4). The

There

brand

previous studies

based

was no evidence

value and

in the

creating

(Infectious Diseases

of Children and

suggesting that

advertisers think

from this study that

additional
ads can

pharmaceutical

demand for their

be

peer-

products.

in the hopes

However,

engineered to target specific customer

the type of content (21). In this study, due to the disproportionate

type,

content of the ads were observed.

define

67

for

more prestigious peer-reviewed journals

have documented that

upon

and

of which,

companies were analyzed

of the total ads analyzed

of ads across journal

period might

company

total of 41 1 product ads,

from 31

non peer-reviewed journals

companies prefer to advertise

distribution

were a

pharmaceutical

display a higher recall rating for the target audience versus the

reviewed journals.

of enhancing

January to June of

frequency of ads varied significantly across the journals

Pediatric News) included 78%
these journals

between

communication process

The

to

professional media recognizes the essential role of

of different products

content.

of pharmaceutical products

the 6-months encompassing

In the 6 journals selected there

physician.

Implications

in the advertising

selected journals within

2002. The focus

segments

and

such

A

no

statistically

significant patterns

in information

more comprehensive analysis over a

trends that relate informational content

longer time

with journal

type

or

target audience.

The data
summary

collected

from the study

of the proportion of answers

agreement

for that

category.

(17%) or half page (5%).
described
significant

for

The majority

Of the

introduction

consistent with

of new products.

of ads were

ads, 55%

study

12

full

addition
page

average of 29%

observations

described in detail below.

in

which shows a

to the coefficient of

(78%) versus multi page

advertised products that were also

the large expense

Notable

in Appendix 3,

each question

multi page

as new compared to an overall

increase is

are presented

(Appendix 3). This

budgets that

regarding the

often

accompany the

content of the ads are

Prescription Drugs
A

between

major

for

ads

focus

of this

prescription and

primarily upon the

assumption

marketplace relative to

and

For
regulations

to

identify patterns in informational content

non-prescription products.

HI

was

developed based

that prescription drugs command a higher price in the

of prescription products

show that

thus HI

is

65%

of the product ads

in

(Appendix 3).

not rejected

Risks

prescription

drug ads,

there is

an expectation

that ads conform to the FDA

regarding fair balance. However, the data show, despite these federal

regulations, 53%

and

prescription ads were
of agreement

by the judges not to be fairly

of prescription ads were perceived

balanced in benefits

nearly

was

OTC drugs. Indeed, the data

the sample were in support

Benefits

study

risks (Appendix 3). Thus, H2 is

found

fair balance

not to contain a

(Ir) for this particular category was 0.94,

these ads were biased in favor

single ad was judged to

have

presented

of presenting

risks in favor

20%

of information.

The

and was therefore

complete agreement on the assessment of the ads

Specifically,

rejected since >

of

coefficient

indicative

of

by each of the judges.
benefits

over

of benefits.

risks,

This is

an

and not one

astounding

finding that warrants closer analysis of ads especially with reference to objective FDA
definitions
of ever
or

increasing FDA regulations that

perceived,

will

be

of ads were perceived

of

DTC

That said,

before publication,

even

whether

they

are real

though the FDA must

other studies

have

shown

that 35%

by the reader to be unbalanced in benefit and risk information (22).

rate of approval of new products

number of new product

expenditures

decrease

ads

advertising practices,

an environment

Product Lifecycle

The
lower

such

permitted to continue.

approve all prescription

Stage

It is hard to believe that in

and subjective reader perceptions.

(6). As

as growth

patent commodity.

is

launches

and a

has been

maximized and sustained until
stage

is

an

since

2001, resulting in a

corresponding decrease in advertising

products proceed through their

Thus, lifecycle

declining

lifecycle,

the available expenditures

finally the product becomes an

important factor in how
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a product

is

off-

A

promoted.

launched

significant proportion of ads were proposed

products such

reality, the data

in

for H3,

a rule

for judgment

support of products

to

with a view

described

for

of pharmaceutical ads are

this category

of 30% was

that 29% of the ads contained specific

recently introduced (Appendix 3). In

ad as new or
were

showed

that

to be in support of newly

new

as

"new",

products,

identifying

view of the

H3 is

a more

identifiers categorizing the

fact that

rejected.

in depth

<

30%

Nevertheless,

of ads

since

29%

analysis was performed on

in the

specific patterns

implemented. In

content of these

"new"

versus maintenance product ads.

Informational Cues
A priori, it is difficult to

being informative.
cue to conclude
on

television

Resnik

ascribe relevant criteria that

Stern focused

and

on

meaningfully define

the inclusion of only one informational

that the ad was informative but their studies

(TV)

ads

an ad as

were performed

originally

to consumers (14). In their analysis, only 49% of TV ads

deemed to be informative based

upon a single

information

the ads contained 2 or more information cues and < 1%

cue.

of ads

were

However, only 16%
had 3 informational

of

cues

(14).
In applying these

criteria

to

professional

journal

series of assumptions were made with regard to the

included in any

First, journals

ad.

(14). Second, it is intuitive that the

the

physician about

of information

of certain

was set

goal of the pharmaceutical

that might

a

be

company is to inform

Third, FDA regulations

types and amounts of information.

to determine

products,

to be more informative than TV

the products benefits versus competitors.

dictate the inclusion
stringency level

quantity

and magazines tend

ads

ads of pharmaceutical

Thus,

a

higher

whether pharmaceutical products ads were

informative.
The
4

of the

results of the

information

contained at

least 6

ads contain at

face
in

of the

cues.
of the

study

showed that

Moreover, 60%
information

least 4 information

cues.

cues.

86%

of the ads were

of ads contained at

Thus, H4 is

These

which ads were

largely non-informative (1 1, 12, 13,

14

least 5,

and

contain at

43%

not rejected since >

numbers are

previously published literature that described

found to

least

of ads

50%

of the

particularly striking in the

patterns of consumer

advertising

14). The implication is that

pharmaceutical product ads

fulfills

do in fact

cater

to the customer

by providing information that

specific needs.

Prescription

and

OTC

ads were

directly compared for information content.

Both

types of ad did not differ statistically with regard to the number of information cues

displayed (Appendix 5).

information

cues per

Moreover,

when compared

ad, prescription

ads

had 5. 1

However, in comparing those ads supporting
differences were

statistical
cues

(Appendix 6). Ads described

such a

difference

informational
widely

might

for

program

cues and

ads

had 5.2

cues.

new products versus maintenance

products,

as

"new"

had only 4.7

be based in the

contained an average of 6.1
cues per ad

greater need

(p
for

=

information

0.0049). The

cues

explanation

a comprehensive

new and unknown products relative

to their

well-known and

accepted maintenance counterparts.

Based

upon

the 14 criteria used to

patterns of informational content were

determine whether

information

on product characteristics and

but

information

cues were not as

other

apparent

from the data that OTC

presenting the packaging
products either

of the

be focused

on

consistently

products

highlighted the packaging

enhancing the

prescription

apparent

safety

product

ad.

or

benefits (98

presented

leverage

brand within the

statistically higher degree than did

an ad

is informative, distinct

identified. As expected, the majority

provided

OTC

OTC

observed with regard to the average number of informational

whereas maintenance products

for

to the overall study average of 5. 1

and

94%, respectively)

(Appendix 3). It

was also

familiarity by way of

Compared to

displayed

of ads

prescription

drugs,

a picture of the product to a

drugs (Appendix 5). This strategy might

of the product

in the

mind of the physician

by reinforcing the message that the OTC product is a well-recognized brand that has been
widely

accepted

in the

marketplace over time.

Disease Identification
A large proportion
not rejected
not contain

Therefore,

of ads

(71%) identified the disease to be treated

(Appendix 3). However, the fact

identifiers

this

data

on what

might

companies with regard

disease

belie

remains that almost

or condition

thus, H5 is

of product ads

the product can be used

assumptions made on

do

for.

the part of pharmaceutical

to the knowledge base of physicians.

15

30%

and

Alternatively,

the

data may

signify

a

deliberate

by the ad to promote

attempt

conditions other than those approved

identification. Prescription
of the ads

apparent that

physicians

capacity to

implemented,

to

revenues.

=

any

and

0.0006) versus only 45% for OTC products (Appendix 5).

assumption made

by the pharmaceutical companies about the

presumably safer, OTC

the

products.

Moreover,

part of the pharmaceutical companies

products, thus

of prescription

increase

To investigate these hypotheses,

innately associate a product with a disease is restricted to the more

relative commitment on

the uses

by the FDA.

drugs for

drug ads identified the disease in a statistically superior

(85%, p

Thus, it is

widely

use of prescription

drug ads were compared to their OTC counterparts with regard to disease

prescription

quantity

"off-label"

No differences

data indicate

to specifically

diminishing the potential for

were seen

the

in the identification

a

identify

"off-label"

promotion
of disease

between

new and maintenance products.

Treatment Directives
Related to the hypothesis

on

disease identification

direction

on

using the

provides

any

indications

additional

or

any

other

or

contained

directives

upon

on

drug usage. Specifically,

these

data,

the

intent

benefits

information

treatment using other

on

impact

communication

only

are

minimal

in

first

forms

directives in

of treatment

dosing

treatment considerations (Appendix

and

subsequently follow up

of the promotional mix.

a product ad

may be

to the targeted physician.

agreement with an earlier

information

of the ads presented

of the pharmaceutical product ad seems

and characteristics

incorporation
the

32%

of ads contained other

the product on

in this study

contra

Only 20% of the ads described treatment

treatment directives.

information while only 13%

on

drug in terms of doses, timing,

dosing of the product, thus H6 is rejected since less than 50% of the ads

directives

3). Based

(H5) is whether or not the ad

was provided

study

on

sell

with

Thus the

superfluous with no ultimate

Moreover,

DTC

clear; to

the results presented

prescription ads

in which

directing the use of the product (22).

Scientific Data

Consistent

with

providing

provide rational evidence

in

relevant

information to

pediatricians

support of a product's effectiveness
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is the

in the form

need

to

of scientific

data. Resnik

and

Stem distinguished between independent

research as sources of such scientific
nature of the scientific

specify the

featured any

between

information

(Appendix 6).

OTC (Appendix

Additionally,

data in

that scientific

data whatsoever,

scientific

prescription and

scientific

information (13). The

only 17%

data may not be

as

key identifiers of the data

presented since

only 35%

of the

differences

displayed

either a chart or graph

containing

(Appendix 3). Collectively, these data

important

a tool to validate product
might

of product ads whose

be thought

primary

goal

of as

is to

benefits

suggest

as was

too complex for

generate maximal

limited time frame.

a

presentation: the role of emotion

The

visual and

copy

aspects of the ads were

patterns

in the

presentation of the

emotion

in the

reader.

rather

the

to

was unable

5) or new versus maintenance products

of ads

support of the product

inclusion into the majority

Ad

study

and there were no significant

assumed, thus H7 is rejected. Scientific data

impact in

current

largely not presented in the ads (Appendix 3). However,

source were
ads

and company-sponsored

It is

possible that

than rational scientific

prescribing
than

physician on

educational value

this study, the

limitations

One

subject to

the interpretation

were

of the

=

the title

or

cues

since

52%

agencies.

study is that

d'etre

this

to

of product advertisements

Interestingly, deficiencies in the
prescription ads

questions

category.

(24). In

by analysis of both images
regarding

emotion are

Nevertheless,

of

the results

contain written emotional cues

No correlation,
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the

instinct"

Consequently there was a lower level

within

on

mislead

drug by appealing to "gut

raison

of ads were judged

body copy of the ad.

impact

educational or

has the capacity to

the ad was addressed

of the reader.

-0.70) between judges

informative

either

of this

induce

are exposed to more emotion

have been previously documented for DTC

and text.

(Ir

advertising

emotion contained within

illustrate any

to its capacity to

predominantly

the qualities of a particular

ever more creative

to

study was to determine whether

informational

logic (23). Indeed this may be the

designed by

agreement

one goal of this

of emotional

order

there might be a resultant negative

professional print media were

The inclusion

emotional.

rather

in the

with regard

if pediatricians

information,

delivery of healthcare. Thus,

products ads

ad, especially

investigated in

either positive or

negative,

in
was

seen

between the

particular ads are

ads

(17

emotional

biased toward

14% for

and

thus there

emotional and scientific aspects of ads,

is

no evidence that

Indeed,

either rational or emotional presentations.

prescription and

OTC, respectively)

information (Appendix 5). No statistically

contained

significant

both

some

scientific and

differences

were seen

in

the emotional content between new and maintenance products (Appendix 6).

It

was of interest

approached significance

to note that the

(p

=

increased level

0.09) relative to

of emotion

prescription

in OTC

product ads

drugs (Appendix 5). Taken

together with the result that these ads also
preferentially incorporated pictures of babies

(50%

vs

20% for

prescription

preferentially utilize
cues

favored

represented

in 38%

have been in the

0.01),

information

the data

of ads

for maintenance

imply that OTC products

cues to stimulate sales rather than the rational

5).

Similarly, baby photographs were

products compared to

(Appendix 6). Collectively, these data
marketplace

protection)

mechanism

=

by prescription drugs (Appendix

new product ads

patent

emotional

ads, p

might

for longer

periods of time

only 1 1%

of the ad.
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=

0.037)

suggest that those products that

(i.e.

are not new and

be forced into the utilization of emotional

to enhance the impact

(p

have lost

messages as a

of

Discussion
The

content analysis presented

practices to physicians

advertising

and

herein

using the

Limitations
fill the gap in the knowledge

attempts to

professional print media.

of

The study was

intentionally focused toward the professional printed media for a variety of reasons:
1

Professional
process

2.

print media occupies a critical position

between

There has been

pharmaceutical

investment
3.

4.

There is

balance the literature relative to the

abundant

provide the platform on which product managers can make
on

the content

there is also

is to increase the

an ethical obligation not

In turn, this

effective

plan and provides

directives

The data highlight
their particular

on

the

to

to

sustain a competitive advantage

promotional mix and

do this

The study targeted

advertising to

ads

at all costs

rather

product, but in

(25). The

than promote

to,

decision-making by the physician

patient.

important

Therefore,

component of the

this study

marketing

content of professional ads.

Thus,

for

that pharmaceutical products follow

depending

the results provide information and guidance to

a particular product.

represents

any decisions

DTC,

for the

sales of the

leveraging the professional media in order to create and

advertising

promotional variables of

enhanced

as an

several patterns

product managers with regard

in

solutions

advertising

classification.

professional print

results

healthcare

recognizes professional print

informed

of pharmaceutical product advertisements.

industry is compelled to accurately educate,

physicians.

information

consumer advertising.

mandate of any product manager

consequently

product

(9).

To

pharmaceutical

that

the documented return on

direct to

pharmaceuticals

upon

upon

professional media

on

The

and

of the printed ad

a need to

decisions

prescribing

is inexplicable based

communication

and physician.

decline specifically in

a recent

expenditures that

company

in the

should

only

be

However, it is

one component of the entire

made

in the

context of the other

medical education and sales

directed toward

physicians overall.

This
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also recognized

force detailing.

pediatricians with a view

assumption was made

in

to representing
order

to perform

a manageable

the target

infant

study; therefore any resultant conclusion must

and thus

are

continuously

may be more susceptible to

surgeon who might

medical

Pediatricians

audience.

disciplines

be

be

exposed to the

emotional cues

to

in the

heartache

versus, say, a

Similar

more concerned with product efficacy.

are warranted

placed

context of
of a sick

cardiovascular

studies on specific

investigate if the conclusions from this study

are

pervasive.

This study

utilized

3 judges

with

different levels

and types of experience

relating

to the medical profession and pharmaceutical industry. While this approach was

beneficial for the

efficient assessment of content

perspective of pediatricians, the
experience within
provided

the healthcare field combined

to each judge

made them

regarding the informational

between the judges
pharmaceutical

intended target

seems

eminently

information, it may not represent the
of the ads.
with

their individual

the comprehensive

qualified

content within the ad.

However,

to

make

Moreover,

training

informed decisions

the extent

of agreement

to affirm any conclusions that were formulated in the pattern

advertising to

pediatricians presented

of

herein.

Summary
This study has

surfaced some profound conclusions

relating to the informational

content of pharmaceutical product ads targeted toward pediatricians:

1

.

Pharmaceutical

98%
2.

For

contain

.

such

highly informative relative to

on product characteristics and

ads, 53%

were perceived

information in

to favor

accordance with

FDA

consumer

ads,

and

benefits.

benefits

over

risks,

rather than

mandates.

Only 7 1% of ads identified the disease or condition for which the product is used.
Moreover,

4.

details

prescription

balance
3

product ads are

ads

Pharmaceutical

information

did

not

typically present treatment

product ads are

cues since

biased toward

only 35%

or

dosing information.

emotional rather

of ads contained scientific

made reference to emotion.

20

than rational

data whereas 52%
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Appendix 1
14 Information Cues (adapted from Resnik & Stern. 1977)
1

.

Product Characteristics: The inherent

durability
2.

Product Benefits: Product performance,
with reference

3.

qualities of the

product, its components,

or engineering.

what

it does

how well, especially

and

to any potential competitive advantages.

Identify Disease: The disease,

syndrome or condition

for which the

product

is

intended.
4.

Taste: Evidence

presented of superior

discriminate from
5.

taste, flavors

or

texture that could

other products.

Nutrition: Evidence

of the nutritional value of the

product,

or

any

reference to

nutritional content.

6.

Packaging/Shape: Reference to the

package or shape of the product that

possibly

confers a competitive advantage.

7.
8.

Safety: What safety features pertain to the product. Is the product safe?
Independent Research: Is the data presented stated to be from an independent
research organization.

9.

Company Research:

Is the data

presented stated to

be from

Company

sponsored

research efforts?

10.

Efficacy/Effectiveness Data:
with

the

"efficacy"

Is the data scientifically relevant, i.e.

associated

"effectiveness."

or

words

11. Scientific Data: Product

relevant scientific

data

in any

presented

form,

e.g.,

graphs or percentages.

12. New/Innovative: The

product's position

"innovative"

13.

"new",
Dosing Regimen:

Doses

or number of doses per

day

targeted)

as

described

by words

"coming

necessary for treatment. Quantities of doses
that could provide differentiation from competitors.

of product

14. Treatment Directives: How to
targeted (or not

in its lifecycle

soon."

or

such as

use

the

groups.

23

drug,

when

to

use

the

drug,

or particular

Appendix 2: Physician Advertisement Content Analysis Questionnaire

Product

Company
Multi-page

Full

Prescription

Yes

No

Risk: Benefits (for

Balanced

Risk >50%

Size

of Ad

prescription

page or

less

Half or less

Benefits >50%

ads)

14 information Cues

Product Characteristics

Yes

No

Product Benefits

Yes

No

Yes

No

Taste

Yes

No

Nutrition

Yes

No

Packaging/Shape

Yes

No

Identify

Disease

Safety

Yes

No

Independent Research

Yes

No

Inconclusive

Company Research
Any Scientific data
Efficacy data

Yes

No

Inconclusive

Yes

No

Yes

No

New/innovative

Yes

No

Dosing regimen

Yes

No

Treatment directives

Yes

No

Photographic

Yes

Drawing/Cartoon

Yes

No

Images
No

Graph/Chart

Yes

No

Product in Package/vial

Yes

No

Object

Yes

No

Animal

Yes

No

Baby/Infant (< 2 yrs)

Yes

No

Toddler (2-4 yrs)
Child (> 4 yrs -18 yrs)

Yes

No

Yes

No

Parent/Adult (>18yrs)

Yes

No

Happy
Suffering

Yes

No

Yes

No

Neutral

Yes

No

Product Benefits in Title

Yes

No

Product Features in Title

Yes

No

Emotional Cues in Title

Yes

No

Product Benefits in Text

Yes

No

Product Features in Text

Yes

No

Emotional Cues in Text

Yes

No

Physician

Yes

No

Copy

Friendly

24

Appendix 3: Summary

(%)
Prescription (%)

Multi-page

Risk: Benefits (for

Balanced

Size

of Ad

prescription

Yes

=

=

0.17

0.65
=

Full

No
0.47

of Results

page or

=

less

=

0.78

Half or less

=

0.05

0.35

Risk >50%

=

0

Benefits >50%

=

0.53

ads)

14 information Cues

YES

NO

0.98

0.02

0.92

Product Benefits

0.94

0.06

0.98

Identify Disease

Inconclusive

Coefficient

of Agreement

Or)
Product Characteristics

(%)

(%)
(%)

0.71

0.29

0.89

Taste (%)

0.13

0.87

0.98

Nutrition

0.11

0.89

0.95

0.52

0.48

0.78

Safety (%)

0.40

0.60

Independent Research

0.03

0.05

0.92

0.99

0.91

0.94

(%)

Packaging/Shape

(%)

0.70

(%)
Company Research (%)
Any Scientific data (%)

0.05

0.04

0.35

0.65

0.92

Efficacy data (%)

0.25

0.75

0.79

New/innovative

(%)
Dosing regimen (%)

0.29

0.71

0.92

0.32

0.68

0.75

Treatment directives

0.13

0.87

0.73

0.70

0.30

0.92

0.33

0.67

0.87

0.17

0.83

0.98

0.54

0.46

1.00

0.22

0.78

0.83

0.11

0.89

0.98

Baby/Infant (< 2 yrs)

(%)
yrs) (%)
Child(>4y-18y)(%)
Parent/Adult (>18 y) (%)
Happy (%)
Suffering (%)
Neutral (%)

0.30

0.70

0.95

Toddler (2

0.14

0.86

0.89

0.27

0.73

0.90

0.14

0.86

1.00

0.49

0.51

0.94

0.11

0.89

0.97

0.17

0.83

0.92

Product Benefits in Title

0.81

0.19

0.81

0.51

0.49

0.81

0.40

0.60

0.72

0.89

0.11

0.89

0.94

0.06

0.87

0.32

0.68

0.67

0.73

0.27

0.88

(%)

Images
Photographic

(%)

Drawing/Cartoon

Graph/Chart

(%)

(%)

Product in Package/vial

Object
Animal

(%)

(%)
(%)
-4

Copy
(%)
Product Features in Title (%)
Emotional Cues in Title (%)
Product Benefits in Text (%)
Product Features in Text (%)
Emotional Cues in Text (%)
Physician Friendly (%)
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Appendix 4
Frequency

of ads across

journal

and over

Jan

Feb

Mar

5

5

5

24

32

Pediatrics

7

Pediatric News

time

(%)
26(6)

June

5

3

3

36

40

36

27

195

6

9

6

6

5

39

19

23

21

25

24

17

129

Pediatric Research

1

1

1

2

1

1

Pediatric Infectious

3

3

3

3

1

2

of Pediatrics

Archives
and Adolescent Medicine
Infectious Diseases

of

Apr

Total

May

Journal

(47)

Children

(10)
(31)
7(2)
15(4)

Disease Journal
Total

(%)

59(15)

70

(17)

26

75

(18)

81

(20)

71(17)

55

(13)

411

(100)

Appendix 5

A Comparison

Information Cues

(avg

of

Prescription

#jper ad)

Disease

(%)
Packaging (%)

*

Statistical

OTC

5.1

5.2

(p 0.10)
0.85 (p
0.0006)

0.45

0.34

0.86

0.37

(%)
Vial Shown (%)
Baby Picture (%)
Emotion (%)
+

Emotion

=

analyses performed

significance was established

>

(p

0.05)

0.90

0.20

0.50

0.24

0.45

0.05)

(p

=

0.00003)

(p
(p
(p

=

0.000004)
0.01)
0.09)

0.32

0.34

0.17 (p>

(%)

OTC Products

Prescription
=

Scientific Data

Scientific Data

versus

=

=

0.14

by one-way analysis of variance (ANOVA) wherein

using

a

i

value

=

0.05.
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Appendix 6
New

products versus

Maintenance

New
Information Cues

#

6.1

products

Maintenance
4.7

Safety (%)

(p 0.0049)
0.50 (p > 0.05)

Scientific Data

0.33

0.36

0.11

0.38

0

0. 16

0.29

0.43

(avg

per

ad)

(%)
Baby Picture (%)
Suffering (%)
Emotion (%)
*

Statistical

analyses performed

significance was established

=

0.36

(p > 0.05)
(p 0.037)
(p 0.078)
(p > 0.05)
=

=

by one-way analysis of variance (ANOVA) wherein

using

a

f

value

=

0.05.
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